ImmuPharma plc (LON:IMM – Get Free Report)’s stock price shot up 4.2% on Friday . The company traded as high as GBX 4.50 ($0.06) and last traded at GBX 3.75 ($0.05). 14,017,531 shares traded hands during mid-day trading, a decline of 25% from the average session volume of 18,651,375 shares. The stock had previously closed at GBX 3.60 ($0.04).
ImmuPharma Stock Up 9.3 %
The company’s 50-day moving average is GBX 1.75 and its two-hundred day moving average is GBX 1.73. The company has a market cap of £16.39 million, a P/E ratio of -393.60 and a beta of 1.53.
About ImmuPharma
ImmuPharma PLC (LSE AIM: IMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company’s portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzorâ„¢), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.
Further Reading
- Five stocks we like better than ImmuPharma
- How to Use the MarketBeat Stock Screener
- Bloom Energy: Powering the Future With Decentralized Energy
- Top Stocks Investing in 5G Technology
- Dividend Powerhouses: Blue-Chip Stocks Built for the Long Haul
- How to Buy Cheap Stocks Step by Step
- Why Traders Are Buying the Dip on Johnson & Johnson Stock
Receive News & Ratings for ImmuPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmuPharma and related companies with MarketBeat.com's FREE daily email newsletter.